Summary of medicine characteristics - D-GAM 250 MICROGRAMS / ML SOLUTION FOR INJECTION
1 NAME OF THE MEDICINAL PRODUCT
D-Gam 250 micrograms/ml solution for injection.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Human anti-D immunoglobulin.
D-Gam 250 micrograms/ml solution for injection:
Human protein content 20 – 180 g/l of which at least 95% is IgG.
Each vial contains 1500 IU* human anti-D immunoglobulin.
One ml contains 1250 IU human anti-D immunoglobulin.
*100 micrograms of human anti-D immunoglobulin correspond to 500 international units (IU).
The potency is determined using the European Pharmacopoeia assay. The equivalence in International Units of the International Reference Preparation is stated by the World Health Organisation.
Distribution of the IgG subclasses (approx. values):
IgG1..........64.3%
IgG2..........29.0%
IgG3..........6.2%
IgG4..........0.5%
The maximum IgA content is 540 micrograms/ml.
Produced from the plasma of human donors.
Excipient with known effect
Sodium content
This medicinal product contains not more than 10 mg (0.5 mmol) sodium per 500 IU dose and per 1500 IU dose which are both essentially ‘sodium-free’.
For the full list of excipients, see section 6.1.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Prevention of Rh(D) immunisation in Rh(D) negative women of childbearing age
Antenatal prophylaxis
> Planned antenatal prophylaxis
> Antenatal prophylaxis following complications of pregnancy including:
Abortion/threatened abortion, ectopic pregnancy or hydatidiform mole, intrauterine foetal death (IUFD), transplacental haemorrhage (TPH) resulting from ante-partum haemorrhage (APH), amniocentesis, chorionic biopsy, obstetric manipulative procedures e.g. external version, invasive interventions, cordocentesis, blunt abdominal trauma or foetal therapeutic intervention
Post-natal prophylaxis
> Delivery of a Rh(D) positive (D, Dweak, Dpartial) baby
Treatment of Rh(D) negative persons after incompatible transfusions of Rh(D) positive blood or other products containing red blood cells e.g. platelet concentrate.
4.2 Posology and method of administration
Posology
The dose of anti-D immunoglobulin should be determined according to the level of exposure to Rh(D) positive red blood cells and based on the knowledge that 0.5 ml of packed Rh(D) positive red blood cells or 1 ml of Rh(D) positive blood is neutralised by approximately 10 micrograms (50 IU) of anti-D immunoglobulin.
The following doses are recommended based on the clinical studies performed with D-Gam.
Prevention of Rh(D) immunisation in Rh(D) negative women
Antenatal prophylaxis.
According to general recommendations, currently administered doses range from 50 –330 micrograms or 250 – 1650 IU
Planned antenatal prophylaxis:
A single dose of 1,500 IU at 28 – 30 weeks of gestation or 500 IU given at both 28 and 34 weeks of gestation.
Antenatal prophylaxis following complications of pregnancy:
A single dose should be administered as soon as possible and within 72 hours and if necessary repeated at 6 – 12 week intervals throughout the pregnancy:
– up to 20 weeks gestation –250 IU minimum
– after 20 weeks gestation – 500 IU per incident. A test for the size of the foetomaternal haemorrhage (FMH) should be performed when anti-D is given after 20 weeks and additional doses of anti-D should be administered as indicated.
Postnatal prophylaxis. According to general recommendations, currently administered doses range from 100 – 300 micrograms or 500 – 1500 IU. If the lower dose (100 micrograms or 500 IU) is administered then testing of the amount of FMH should be performed.
The recommended dose is 500 IU.
For postnatal use, the product should be administered to the mother as soon as possible within 72 hours of delivery of a Rh positive (D, Dweak, Dpartial) infant. If more than 72 hours have elapsed, the product should not be withheld but administered as soon as possible.
The postnatal dose must still be given even when antenatal prophylaxis has been administered and even if residual activity from antenatal prophylaxis can be demonstrated in maternal serum.
If a large FMH (> 4 ml (0.7%-0.8% of women)) is suspected, e.g. in the event of foetal/neonatal anaemia or intrauterine foetal death, its extent should be determined by a suitable method e.g. Kleihauer-Betke acid elution test to detect foetal haemoglobin (HbF) or flow cytometry which specifically identifies RhD positive cells. Additional doses of anti-D immunoglobulin should be administered accordingly (10 micrograms or 50 IU) per 0.5 ml foetal red blood cells).
Incompatible transfusions of red blood cells (RBCs)
The recommended dose is 20 micrograms (100 IU) anti-D immunoglobulin per 2 ml of transfused Rh(D) positive blood or per 1 ml of RBC concentrate. It is recommended that there is a consultation with a specialist in transfusion medicine in order to evaluate the feasibility of a red cell exchange procedure to reduce the load of D positive red cells in circulation and to define the dose of anti-D immunoglobulin required to suppress immunisation. Follow-up tests for D positive red cells should be undertaken every 48 hours and further anti-D given until there are no detectable D positive red cells in circulation. In any case, due to possible risk of haemolysis it is suggested to not exceed a maximum dose of 3,000 micrograms (15,000 IU).
The use of an alternative intravenous product is recommended as it will achieve adequate plasma levels immediately. If no intravenous product is available, the very large volume should be administered intramuscularly over a period of several days (see section 4.4).
Paediatric population
The safety and efficacy of D-Gam in children aged 0–18 years has not been established. No data are available.
Method of administration
Intramuscular use.
The usual recommended site for intramuscular injection for adults is the deltoid.
If a large volume (> 2 ml for children or > 5 ml for adults) is required, it is recommended to administer this in divided doses at different sites.
If intramuscular administration is contra-indicated (bleeding disorders), an alternative intravenous product should be used.
Overweight/obese patients
In case of overweight/obese patients the use of an intravenous anti-D product should be considered (see section 4.4).
4.3 Contraindications
The product is not intended for use in Rh(D) positive individuals.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see section 4.4).
Hypersensitivity to human immunoglobulins especially in patients with antibodies against IgA.
4.4 Special warnings and precautions for use
Ensure that D-Gam is not administered into a blood vessel, because of the risk of shock.
In the case of post-natal use, the product is intended for maternal administration. It should not be given to the new-born infant.
The product is not intended for use in Rh(D) positive individuals.
Hypersensitivity
True hypersensitivity reactions are rare but allergic type responses to anti-D immunoglobulin may occur.
D-Gam contains a small quantity of IgA. Although anti-D immunoglobulin has been used successfully in selected IgA deficient individuals, individuals who are deficient in IgA have the potential for developing IgA antibodies and may have anaphylactic reactions after administration of plasma derived medicinal products containing IgA. The physician must therefore weigh the benefit of treatment with D-Gam against the potential risks of hypersensitivity reactions.
Rarely, human anti-D immunoglobulin can induce a fall in blood pressure with anaphylactic reaction, even in patients who have tolerated previous treatment with human immunoglobulin.
Suspicion of allergic or anaphylactic type reactions requires immediate discontinuation of the injection. In case of shock, standard medical treatment for shock should be implemented.
Haemolytic reactions
Patients in receipt of incompatible transfusion, who receive very large doses of anti-D immunoglobulin, should be monitored clinically and by biological parameters, because of the risk of haemolytic reaction.
Thromboembolism
Arterial and venous thromboembolic events including myocardial infarction, stroke, deep venous thrombosis and pulmonary embolism have been associated with the use of immunoglobulins. Although thromboembolic events have not been observed for D-Gam, patients should be sufficiently hydrated before use of immunoglobulins. Caution should be exercised in patients with pre-existing risk factors for thrombotic events (such as hypertension, diabetes mellitus and a history of vascular disease or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, patients with prolonged periods of immobilisation, severely hypovolemic patients, patients with diseases which increase blood viscosity), especially when higher doses of D-Gam are prescribed.
Patients should be informed about first symptoms of thromboembolic events including shortness of breath, pain and swelling of a limb, focal neurological deficits and chest pain and should be advised to contact their physician immediately upon onset of symptoms.
Interference with serological testing
After injection of immunoglobulin the transitory rise of the various passively transferred antibodies in the patient’s blood may result in misleading positive results in serological testing.
Passive transmission of antibodies to erythrocyte antigens, e.g. A, B, D may interfere with some serological tests for red cell antibodies, for example the antiglobulin test (Coombs’ test) particularly in Rh(D) positive neonates whose mothers have received antenatal prophylaxis.
Overweight/obese patients
In overweight/obese patients, due to the possible lack of efficacy in case of intramuscular administration, an intravenous anti-D product is recommended.
Transmissible agents
Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) and for the non-enveloped hepatitis A and parvovirus B19 viruses.
There is reassuring clinical experience regarding the lack of hepatitis A or parvovirus B19 transmission with immunoglobulins and it is also assumed that the antibody content makes an important contribution to the viral safety.
It is strongly recommended that every time that D-Gam is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.
4.5 Interaction with other medicinal products and other forms of interaction
Live attenuated virus vaccines
Active immunisation with live virus vaccines (e.g. measles, mumps or rubella) should be postponed for 3 months after the last administration of anti-D immunoglobulin, as the efficacy of the live virus vaccine may be impaired.
If anti-D immunoglobulin needs to be administered within 2–4 weeks of a live virus vaccination, then the efficacy of such a vaccination may be impaired.
No interaction studies have been performed.
4.6 Fertility, pregnancy and lactation
Pregnancy
This medicinal product is intended for use in pregnancy.
Breast-feeding
This medicinal product can be used during breast-feeding.
Immunoglobulins are excreted in human milk and may contribute to protecting the neonate from pathogens which have a mucosal port of entry.
Fertility
No animal fertility studies have been conducted with D-Gam. Clinical experience with human anti-D immunoglobulin suggests that no harmful effects are to be expected.
4.7 Effects on ability to drive and use machines
D-Gam has no influence on the ability to drive and use machines.
4.8 Undesirable effects
Summary of the safety profile
Adverse reactions such as chills, headache, dizziness, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally.
Rarely human immunoglobulins may cause a sudden fall in blood pressure and, in isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration.
Local reactions at administration sites: swelling, soreness, redness, induration, local heat, itching, bruising and rash.
The following adverse reactions have been reported from post-marketing experience.
Tabulated list of adverse reactions
The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level).
Frequencies have been evaluated according to the following convention: Very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1,000 to <1/100); rare (>1/10,000 to <1,1000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
| MedDRA Standard System Organ Class | Adverse reaction | Frequency |
| Immune system disorders | Hypersensitivity, anaphylactic shock | Rare |
| Nervous system disorders | Headache | Not known |
| Cardiac disorders | Tachycardia | Not known |
| Vascular disorders | Hypotension | Rare |
| Gastrointestinal disorders | Nausea, vomiting | Not known |
| Skin and subcutaneous tissue disorders | Skin reaction, erythema, pruritus | Not known |
| Musculoskeletal and connective tissue disorders | Arthralgia, back pain | Not known |
| General disorders and administration site conditions | Pyrexia, malaise, chills At the injection site: swelling, pain, erythema, induration, warmth, pruritus, rash | Not known |
For safety information with respect to transmissible agents, see section 4.4.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9 Overdose
4.9 OverdoseConsequences of an overdose are not known.
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: immune sera and immunoglobulins, immunoglobulins, specific immunoglobulins: anti-D (Rh) immunoglobulin, ATC code: J06BB01.
Anti-D immunoglobulin contains specific antibodies (IgG) against the D (Rh) antigen of human erythrocytes.
It can also contain antibodies to other Rh antigens e.g. anti-Rh C antibodies.
During pregnancy, and especially at the time of childbirth, foetal red blood cells may enter the maternal circulation. When the woman is Rh(D)-negative and the foetus Rh(D)-positive, the woman may become immunised to the Rh(D) antigen and produce anti-Rh(D) antibodies which cross the placenta and may cause haemolytic disease of the newborn. Passive immunisation with anti-D immunoglobulin prevents Rh(D) immunisation in more than 99% of cases provided that a sufficient dose of anti-D immunoglobulin is administered soon enough after exposure to Rh(D)-positive foetal red blood cells.
The mechanism by which anti-D immunoglobulin suppresses immunisation to Rh(D)-positive red cells is not known. Suppression may be related to the clearance of the red cells from the circulation before they reach immunocompetent sites or, it may be due to more complex mechanisms involving recognition of foreign antigen and antigen presentation by the appropriate cells at the appropriate sites in the presence or absence of antibody.
5.2 Pharmacokinetic properties
Absorption and Distribution
Human anti-D immunoglobulin for intramuscular administration is slowly absorbed into the recipient’s circulation and reaches a maximum after a delay of 2–3 days.
Human anti-D immunoglobulin has a half-life of about 3–4 weeks. This half-life may vary from patient to patient.
Biotransformation and Elimination
IgG and IgG-complexes are broken down in cells of the reticuloendothelial system.
5.3 Preclinical safety data
5.3 Preclinical safety dataD-Gam is a preparation of human plasma proteins, so safety testing in animals is not particularly relevant to the safety of use in man. Acute toxicity studies in rat and mouse showed species specific reactions, which bear no relevance to administration in humans.
Repeated dose safety testing is impracticable due to the induction of and interference with antibodies to human protein. Clinical experience provides no sign of tumourigenic and mutagenic effects.
6.1 List of excipients
Sodium chloride
Glycine
Sodium acetate
6.2 Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
6.3 Shelf life
2 years.
Once a vial has been opened, the solution should be used immediately.
6.4 Special precautions for storage
Store in a refrigerator (2°C – 8°C).
Do not freeze.
Keep the vial in the outer carton in order to protect from light.
Storage for up to one week at room temperature (25 DC) in the original container is not detrimental.
For storage conditions after first opening of the medicinal product, see section 6.3.
6.5 Nature and contents of container
5 ml glass vial (Type I Ph.Eur.) closed with a halobutyl stopper and over-sealed with a tamper-evident cap.
D-Gam vials are for single use only.
Pack sizes
D-Gam 50 micrograms/ml solution for injection
1 × 500 IU vial
D-Gam 250 micrograms/ml solution for injection
1 × 1500 IU vial
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
6.6 Special precautions for disposalThe product should be brought to room or body temperature before use.
Do not use solutions that are cloudy or have deposits.
Any unused product or waste material should be disposed of in accordance with local requirements.
7 MARKETING AUTHORISATION HOLDER
Bio Products Laboratory Ltd., Elstree, WD6 3BX.
United Kingdom.
8 MARKETING AUTHORISATION NUMBER(S)
PL 08801/0048 – 500 IU dose size.
PL 08801/0049 – 1500 IU dose size.
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
31 July 2000